Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wainwright

Showing results (101-110 of 140) with videos related to

Pageof 14
Sort By:
Brain, Behavior, and Immunity|February 10, 2017
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastomaLijie Zhai, Erik Ladomersky, Carlos R Dostal, et al.
Cancer Gene Therapy|January 18, 2014
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant gliomaB Thaci, A U Ahmed, I V Ulasov, et al.
Brain, Behavior, & Immunity - Health|March 20, 2020
A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitorsSebastian Otto-Meyer, Rian DeFaccio, Corey Dussold, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 31, 2015
Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant GliomaMahua Dey, Alan L Chang, Jason Miska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2014
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumorsDerek A Wainwright, Alan L Chang, Mahua Dey, et al.
Oncoimmunology|February 7, 2019
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg <i>et al</i>. (2017)Lijie Zhai, Erik Ladomersky, Kristen L Lauing, et al.
Oncoimmunology|September 14, 2016
Improving vaccine efficacy against malignant gliomaErik Ladomersky, Matthew Genet, Lijie Zhai, et al.
The European Journal of Neuroscience|September 15, 2001
Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the ratK R Oliver, S A Kane, C A Salvatore, et al.
Journal for Immunotherapy of Cancer|September 20, 2017
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancerAndrew Zloza, A Karolina Palucka, Lisa M Coussens, et al.
Frontiers in Immunology|October 25, 2021
CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal DiseaseHinda Najem, Anantha Marisetty, Craig Horbinski, et al.
Pageof 14

Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
Brain, Behavior, and Immunity|February 10, 2017
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastomaLijie Zhai, Erik Ladomersky, Carlos R Dostal, et al.
Cancer Gene Therapy|January 18, 2014
Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant gliomaB Thaci, A U Ahmed, I V Ulasov, et al.
Brain, Behavior, & Immunity - Health|March 20, 2020
A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitorsSebastian Otto-Meyer, Rian DeFaccio, Corey Dussold, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 31, 2015
Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant GliomaMahua Dey, Alan L Chang, Jason Miska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2014
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumorsDerek A Wainwright, Alan L Chang, Mahua Dey, et al.
Oncoimmunology|February 7, 2019
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg <i>et al</i>. (2017)Lijie Zhai, Erik Ladomersky, Kristen L Lauing, et al.
Oncoimmunology|September 14, 2016
Improving vaccine efficacy against malignant gliomaErik Ladomersky, Matthew Genet, Lijie Zhai, et al.
The European Journal of Neuroscience|September 15, 2001
Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the ratK R Oliver, S A Kane, C A Salvatore, et al.
Journal for Immunotherapy of Cancer|September 20, 2017
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancerAndrew Zloza, A Karolina Palucka, Lisa M Coussens, et al.
Frontiers in Immunology|October 25, 2021
CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal DiseaseHinda Najem, Anantha Marisetty, Craig Horbinski, et al.
Pageof 14